Back to Search
Start Over
Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands
- Source :
- PLoS Medicine, 17(9). PUBLIC LIBRARY SCIENCE, PLOS Medicine, PLoS Medicine, PLoS Medicine, Vol 17, Iss 9, p e1003296 (2020)
-
Abstract
- Background Based on different genetic and environmental risk factors and histology, it has been proposed that rheumatoid arthritis (RA) consists of 2 types: autoantibody-positive and autoantibody-negative RA. However, until now, this remained hypothetical. To assess this hypothesis, we studied whether the long-term outcomes differed for these 2 groups of RA patients. Methods and findings In the Leiden Early Arthritis Clinic cohort, 1,285 consecutive RA patients were included between 1993 and 2016 and followed yearly. Treatment protocols in routine care improved over time, irrespective of autoantibody status, and 5 inclusion periods were used as instrumental variables: 1993–1996, delayed mild disease-modifying antirheumatic drug (DMARD) initiation (reference period); 1997–2000, early mild DMARDs; 2001–2005, early methotrexate; 2006–2010, early methotrexate followed by treat-to-target adjustments; 2011–2016, similar to 2006–2010 plus additional efforts for very early referral. Three long-term outcomes were studied: sustained DMARD-free remission (SDFR) (persistent absence of clinical synovitis after DMARD cessation), mortality, and functional disability measured by yearly Health Assessment Questionnaire (HAQ). Treatment response in the short term (disease activity) was measured by Disease Activity Score–28 with erythrocyte sedimentation rate (DAS28-ESR). Linear mixed models and Cox regression were used, stratified for autoantibody positivity, defined as IgG anti-CCP2 and/or IgM rheumatoid factor positivity. In total, 823 patients had autoantibody-positive RA (mean age 55 years, 67% female); 462 patients had autoantibody-negative RA (age 60 years, 64% female). Age, gender, and percentage of autoantibody-positive patients were stable throughout the inclusion periods. Disease activity significantly decreased over time within both groups. SDFR rates increased after introduction of treat-to-target (hazard ratio [HR] 2006–2010 relative to 1993–1996: 3.35 [95% CI 1.46 to 7.72; p = 0.004]; HR 2011–2016: 4.57 [95% CI 1.80 to 11.6; p = 0.001]) in autoantibody-positive RA, but not in autoantibody-negative RA. In autoantibody-positive RA, mortality decreased significantly after the introduction of treat-to-target treatment adjustments (HR 2006–2010: 0.56 [95% CI 0.34 to 0.92; p = 0.023]; HR 2011–2016: 0.33 [95% CI 0.14 to 0.77; p = 0.010]), but not in autoantibody-negative RA (HR 2006–2010: 0.79 [95% CI 0.40 to 1.56; p = 0.50]; HR 2011–2016: 0.36 [95% CI 0.10 to 1.34; p = 0.13]). Similarly, functional disability improved in autoantibody-positive RA for the periods after 2000 relative to 1993–1996 (range −0.16 [95% CI −0.29 to −0.03; p = 0.043] to −0.32 [95% CI −0.44 to −0.20; p < 0.001] units of improvement), but not in autoantibody-negative RA (range 0.10 [95% CI −0.12 to 0.31; p = 0.38] to −0.13 [95% CI −0.34 to 0.07; p = 0.20] units of improvement). Limitations to note were that treatment was not randomized—but it was protocolized and instrumental variable analysis was used to obtain comparable groups—and that a limited spread of ethnicities was included. Conclusions Although disease activity has improved in both autoantibody-positive and autoantibody-negative RA in recent decades, the response in long-term outcomes differed. We propose that it is time to subdivide RA into autoantibody-positive RA (type 1) and autoantibody-negative RA (type 2), in the hope that this leads to stratified treatment in RA.<br />In a longitudinal cohort study, Xanthe Matthijssen and colleagues investigate differences between autoantibody-positive and -negative RA.<br />Author summary Why was this study done? Patients with rheumatoid arthritis (RA) have different risk factors and histology (microscopic anatomy) depending on the presence or absence of autoantibodies (anti-citrullinated protein antibodies and rheumatoid factor). Because it is suspected that RA with and without autoantibodies are 2 distinct diseases with different pathophysiology, we hypothesized that these 2 types of RA will have reacted differently to improvements in treatment strategies that have taken place over the last decades. What did the researchers do and find? Since its start in 1993, the inclusion criteria of the Leiden Early Arthritis Clinic cohort have not changed, and included RA patients have remained similar, apart from earlier diagnosis; therefore, RA patients from different years were comparable. Treatment protocols enhanced over time, but were similar for patients with and without autoantibodies. We studied the changes in disease activity and 3 long-term outcomes of RA patients with and without autoantibodies over time (inclusion period was a proxy for treatment strategy). We found that while disease activity improved in both patient groups, the long-term outcomes (the possibility to permanently stop medication, mortality, and functional disability) only improved in RA patients with autoantibodies. What do these findings mean? The disconnection between improvement in disease activity and subsequent improvement in long-term outcomes in RA without autoantibodies suggests that the underlying pathogenesis of RA with and without autoantibodies is different. We propose that it is time to formally subdivide RA into type 1 (with autoantibodies) and type 2 (without autoantibodies).
- Subjects :
- Male
Physiology
Epidemiology
NSAIDs
Arthritis
030204 cardiovascular system & hematology
Biochemistry
Severity of Illness Index
Biomarkers, Pharmacological
Arthritis, Rheumatoid
Cohort Studies
0302 clinical medicine
Animal Cells
Materials Physics
Immune Physiology
Red Blood Cells
Medicine and Health Sciences
030212 general & internal medicine
Longitudinal Studies
10. No inequality
Netherlands
Analgesics
Immune System Proteins
medicine.diagnostic_test
Physics
Hazard ratio
Drugs
General Medicine
Middle Aged
3. Good health
Rheumatoid arthritis
Erythrocyte sedimentation rate
Antirheumatic Agents
Cohort
Physical Sciences
Disease Progression
Medicine
Female
Cellular Types
Sedimentation
Cohort study
Research Article
Adult
medicine.medical_specialty
Immunology
Materials Science
Rheumatoid Arthritis
Antibodies
Autoimmune Diseases
03 medical and health sciences
Rheumatology
Internal medicine
Severity of illness
medicine
Humans
Autoantibodies
Aged
Pharmacology
Blood Cells
Proportional hazards model
business.industry
Biology and Life Sciences
Proteins
Cell Biology
medicine.disease
Pain management
Methotrexate
Medical Risk Factors
Clinical Immunology
Clinical Medicine
business
Subjects
Details
- Language :
- English
- ISSN :
- 15491676
- Volume :
- 17
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- PLOS Medicine
- Accession number :
- edsair.doi.dedup.....bdf4d1d2ccd201ae66df4a08f20a613d
- Full Text :
- https://doi.org/10.1371/journal.pmed.1003296